OBJECTIVES: Abnormalities in auditory steady state response (ASSR) at gamma range frequencies have been found in bipolar disorder, but the relationship of these neurophysiological disturbances to clinical factors has not been well characterized. We therefore evaluated the ASSR in bipolar disorder and examined its sensitivity to clinical symptoms, cognitive function, and pharmacological treatment. METHODS: A total of 68 patients with bipolar disorder and 77 control participants were evaluated. Click trains presented at 20, 30, 40, and 50 Hz evoked ASSRs. Mean trial power (MTP) and phase locking factor (PLF) measured response magnitude and phase synchronization of the ASSR at each stimulation frequency. Clinical state, pharmacological treatment, and neuropsychological performance were assessed, and their respective relationships with ASSR measures were evaluated. RESULTS: Patients with bipolar disorder showed reduced MTP and PLF compared to control participants. Bipolar disorder patients taking psychotropic medications had decreased PLF relative to patients withdrawn from medications. Control participants performed better on neuropsychological tests than bipolar disorder patients; however, test scores did not correlate with ASSR measures. CONCLUSIONS: Deficits in the generation and maintenance of ASSR are present in bipolar disorder, implicating disturbances in auditory pathways. ASSR may be sensitive to medication status. Other clinical features, including mood state, psychotic features, cognitive performance, smoking, or history of substance use disorder, were unrelated to MTP or PLF.
OBJECTIVES:Abnormalities in auditory steady state response (ASSR) at gamma range frequencies have been found in bipolar disorder, but the relationship of these neurophysiological disturbances to clinical factors has not been well characterized. We therefore evaluated the ASSR in bipolar disorder and examined its sensitivity to clinical symptoms, cognitive function, and pharmacological treatment. METHODS: A total of 68 patients with bipolar disorder and 77 control participants were evaluated. Click trains presented at 20, 30, 40, and 50 Hz evoked ASSRs. Mean trial power (MTP) and phase locking factor (PLF) measured response magnitude and phase synchronization of the ASSR at each stimulation frequency. Clinical state, pharmacological treatment, and neuropsychological performance were assessed, and their respective relationships with ASSR measures were evaluated. RESULTS:Patients with bipolar disorder showed reduced MTP and PLF compared to control participants. Bipolar disorderpatients taking psychotropic medications had decreased PLF relative to patients withdrawn from medications. Control participants performed better on neuropsychological tests than bipolar disorderpatients; however, test scores did not correlate with ASSR measures. CONCLUSIONS: Deficits in the generation and maintenance of ASSR are present in bipolar disorder, implicating disturbances in auditory pathways. ASSR may be sensitive to medication status. Other clinical features, including mood state, psychotic features, cognitive performance, smoking, or history of substance use disorder, were unrelated to MTP or PLF.
Authors: Maria A Pastor; Julio Artieda; Javier Arbizu; Josep M Marti-Climent; Ivan Peñuelas; Jose C Masdeu Journal: J Neurosci Date: 2002-12-01 Impact factor: 6.167
Authors: Benicio N Frey; Giovana B Zunta-Soares; Sheila C Caetano; Mark A Nicoletti; John P Hatch; Paolo Brambilla; Alan G Mallinger; Jair C Soares Journal: Eur Neuropsychopharmacol Date: 2008-06-12 Impact factor: 4.600
Authors: S Leonard; L E Adler; K Benhammou; R Berger; C R Breese; C Drebing; J Gault; M J Lee; J Logel; A Olincy; R G Ross; K Stevens; B Sullivan; R Vianzon; D E Virnich; M Waldo; K Walton; R Freedman Journal: Pharmacol Biochem Behav Date: 2001-12 Impact factor: 3.533
Authors: J S Kwon; B F O'Donnell; G V Wallenstein; R W Greene; Y Hirayasu; P G Nestor; M E Hasselmo; G F Potts; M E Shenton; R W McCarley Journal: Arch Gen Psychiatry Date: 1999-11
Authors: Anabel Martínez-Arán; Eduard Vieta; María Reinares; Francesc Colom; Carla Torrent; Jose Sánchez-Moreno; Antonio Benabarre; José Manuel Goikolea; Mercè Comes; Manel Salamero Journal: Am J Psychiatry Date: 2004-02 Impact factor: 18.112
Authors: Patrick D Skosnik; Deepak C D'Souza; Adam B Steinmetz; Chad R Edwards; Jennifer M Vollmer; William P Hetrick; Brian F O'Donnell Journal: Neuropsychopharmacology Date: 2012-06-20 Impact factor: 7.853
Authors: Olga Rass; Jennifer K Forsyth; Giri P Krishnan; William P Hetrick; Mallory J Klaunig; Alan Breier; Brian F O'Donnell; Colleen A Brenner Journal: Schizophr Res Date: 2012-01-28 Impact factor: 4.939
Authors: Patrick D Skosnik; Giri P Krishnan; Deepak C D'Souza; William P Hetrick; Brian F O'Donnell Journal: Neuropsychopharmacology Date: 2014-07-03 Impact factor: 7.853
Authors: Mei-Hua Hall; Chia-Yen Chen; Bruce M Cohen; Kevin M Spencer; Deborah L Levy; Dost Öngür; Jordan W Smoller Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2015-03-04 Impact factor: 3.568
Authors: Daisuke Koshiyama; Makoto Miyakoshi; Yash B Joshi; Juan L Molina; Kumiko Tanaka-Koshiyama; Joyce Sprock; David L Braff; Neal R Swerdlow; Gregory A Light Journal: Neuropsychopharmacology Date: 2020-08-22 Impact factor: 7.853
Authors: Tian-Hang Zhou; Nora E Mueller; Kevin M Spencer; Sonal G Mallya; Kathryn Eve Lewandowski; Lesley A Norris; Deborah L Levy; Bruce M Cohen; Dost Öngür; Mei-Hua Hall Journal: Schizophr Res Date: 2018-05-26 Impact factor: 4.939
Authors: Olga Rass; Jennifer K Forsyth; Amanda R Bolbecker; William P Hetrick; Alan Breier; Paul H Lysaker; Brian F O'Donnell Journal: Schizophr Res Date: 2012-06-09 Impact factor: 4.939